Literature DB >> 11958854

Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor.

G Cavaletti1, G Pezzoni, C Pisano, N Oggioni, F Sala, C Zoia, C Ferrarese, P Marmiroli, G Tredici.   

Abstract

The pathogenesis of the neurotoxicity of most antineoplastic drugs is unknown. Recent reports suggest that changes in the circulating levels of nerve growth factor (NGF) might be related to the dorsal root ganglia sensory neuron damage induced by cisplatin (CDDP), the first member of a family of widely used and very effective platinum-derived anticancer agents. Using a well-characterized model of CDDP neurotoxicity, we demonstrated that the NGF circulating level decreased during chronic CDDP administration in close accordance with the clinical course and returned to normal levels after recovery from the neurotoxic damage. Moreover, these changes were restricted to NGF and did not involve other trophic factors of the same neurotrophin family. Our findings are in agreement with previous in vitro and in vivo results and further suggest that NGF plays a specific role in the course of CDDP-induced primary sensory neuron damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11958854     DOI: 10.1016/s0304-3940(02)00091-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Pain in cancer survivors.

Authors:  Matthew Rd Brown; Juan D Ramirez; Paul Farquhar-Smith
Journal:  Br J Pain       Date:  2014-11

3.  Non-cytotoxic Concentration of Cisplatin Decreases Neuroplasticity-Related Proteins and Neurite Outgrowth Without Affecting the Expression of NGF in PC12 Cells.

Authors:  Rafaela Scalco Ferreira; Neife Aparecida Guinaim Dos Santos; Nádia Maria Martins; Laís Silva Fernandes; Antonio Cardozo Dos Santos
Journal:  Neurochem Res       Date:  2016-07-29       Impact factor: 3.996

4.  Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats.

Authors:  Ahmed A Abdelsameea; Soad L Kabil
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-03       Impact factor: 3.000

Review 5.  Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Yaqin Han; Maree T Smith
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

6.  Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity.

Authors:  Jing Zhu; Valentina Alda Carozzi; Nicole Reed; Ruifa Mi; Paola Marmiroli; Guido Cavaletti; Ahmet Hoke
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

7.  Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies.

Authors:  Jeonghwan Youk; Young-Sook Kim; Jung-Ah Lim; Dong-Yeop Shin; Youngil Koh; Soon-Tae Lee; Inho Kim
Journal:  PLoS One       Date:  2017-08-21       Impact factor: 3.240

8.  Protective effect of bioactive compounds from Echinophora cinerea against cisplatin-induced oxidative stress and apoptosis in the PC12 cell line.

Authors:  Yald Shokoohinia; Shekoufeh Khajouei; Farahnaz Ahmadi; Nastaran Ghiasvand; Leila Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2017-04       Impact factor: 2.699

Review 9.  Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.

Authors:  Paul B Tchounwou; Shaloam Dasari; Felicite K Noubissi; Paresh Ray; Sanjay Kumar
Journal:  J Exp Pharmacol       Date:  2021-03-18

Review 10.  Chemotherapy induced peripheral neuropathic pain.

Authors:  Hue Jung Park
Journal:  Korean J Anesthesiol       Date:  2014-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.